DUSE/Y7G (DUSE/Y7G)

Dusseldorf Stock Exchange: DUSE/Y7G · EUR

€5.38

-3.85 (-41.8%)· Recorded snapshot

Market cap	225.3M
Revenue (ttm)	9.1M
Net income (ttm)	-82.7M
EPS (ttm)	-€2.13
Volume	1,700

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 9.1M
Net income (ttm): -82.7M
EPS (ttm): -€2.13
Market cap: 225.3M

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-28.2

P25 n/aP50 n/aP75 n/a

ROIC-19.5

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All DUSE/Y7G indicators

Market & fundamental data

Available fields

144

Groups with data

Currency

USD

Showing 144 of 144 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	EUR
Country	United States
Country code	DE
Earnings date	2026-11-05
Employees	61
Employees change	-2
Employees growth	-3.13%
Enterprise value	EUR -114.3M
Exchange	Dusseldorf Stock Exchange
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-10-10
Fiscal year end	December
Founded	2015
Industry	Drug Manufacturers - Specialty & Generic
Is primary listing	No
ISIN number	US09077V1008
Last refreshed	2026-10-28
Market cap	EUR 225.3M
Next earnings date	2026-11-05
Price	EUR 5.38
Price currency	EUR
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-06
Symbol	duse/Y7G
Website	https://bioagelabs.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-39.62%
FCF / EV yield	67.45%
FCF yield	-34.22%
Industry forward P/E	17.12x
Industry P/E	27.78x
P/B ratio	0.69x
P/S ratio	24.86x
Price / tangible book value	0.69x
Sector forward P/E	14.71x
Sector P/E	39.68x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Operating margin	-1,026.28%
Pretax margin	-912.25%
Profit per employee	EUR -1.4M
Revenue per employee	EUR 148,586
ROA	-18.47%
ROCE	-28.14%
ROE	-28.21%
ROIC	-19.5%
SBC / revenue	135.57%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	2
Net income growth years	0
Revenue growth	168.06%
Revenue growth (Q)	1.62%
Revenue growth (QoQ)	-11.58%
Revenue growth quarters	2
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	EUR -427,146
Depreciation and amortization	EUR 225,423
EBIT	EUR -93M
EBITDA	EUR -92.8M
EPS	EUR -2.13
Financing cash flow	EUR 134.9M
Free cash flow	EUR -77.1M
Free cash flow minus SBC	EUR -89.4M
Gross profit	EUR -67.8M
Investing cash flow	EUR -186.3M
Net borrowing	EUR -4.5M
Net cash flow	EUR -128.1M
Net income	EUR -82.7M
Operating cash flow minus SBC	EUR -89M
Operating income	EUR -93M
Revenue	EUR 9.1M
Stock-based compensation	EUR 12.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	12.72
Book value per share	EUR 7.17
Debt / equity	0.01
Interest coverage	-378.19
Long-term assets	EUR 50.8M
Long-term liabilities	EUR 2M
Net cash (debt)	EUR 331.2M
Net cash / market cap	147.01%
Net cash growth	24.21%
Net debt / equity	-1.01
Piotroski F-Score	4
Property, plant and equipment	EUR 3.4M
Shareholders' equity	EUR 328.2M
Tangible book value	EUR 328.2M
Tangible book value per share	EUR 7.17
Total assets	EUR 347.4M
Total cash	EUR 279M
Total debt	EUR 2.5M
Total liabilities	EUR 19.3M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.03
Current assets	EUR 296.7M
Current liabilities	EUR 17.3M
Current ratio	17.19
Net working capital	EUR -6.1M
Quick ratio	16.75
Working capital	EUR 272.3M
Working capital turnover	0.03

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-43.29%
Shareholder yield	-43.29%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1D price change	-41.77%
1M price change	-41.77%
1M total return	-41.77%
20-day SMA	EUR 10.24
3M price change	-60.24%
3M total return	-60.24%
52-week high	EUR 18.70
52-week high date	2026-02-09
52-week low	EUR 5.38
52-week low date	2026-10-06
6M price change	-61.33%
6M total return	-61.33%
All-time high	EUR 24.10
All-time high date	2024-10-22
All-time low	EUR 3.42
All-time low date	2025-06-04
Average true range (ATR)	EUR 2.28
Average volume	357.1
Change from 52-week high	-71.26%
Change from 52-week low	0%
Change from all-time high	-77.7%
Change from all-time low	57.16%
Change from open	-3.33%
Day's gap	-39.76%
Dollar volume	EUR 9,138
High price	EUR 5.81
Low price	EUR 5.38
Monthly RSI	0
Open price	EUR 5.56
Position in 52-week range	0%
Previous close	EUR 9.23
Price vs 20-day SMA	-47.49%
Relative volume	4.76
RSI	33.16
Sharpe ratio	1.1
Sortino ratio	4.23
Volume	1.7K
Weekly RSI	0

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	39.2M
Shares change (QoQ)	5.55%
Shares change (YoY)	43.29%
Shares held by insiders	2.36%
Shares held by institutions	76.93%
Short ratio	3.6 days

Deeper analysis on DUSE/Y7G

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this DUSE/Y7G report

Is a complete DUSE/Y7G research report available?

No complete published report is available for duse/Y7G (DUSE/Y7G) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

DUSE/Y7G (DUSE/Y7G)

Price

Financial snapshot

Fair-value bridge

Latest news · DUSE/Y7G

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All DUSE/Y7G indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on DUSE/Y7G

Frequently asked questions